Aravive to Participate In-Person at 34th Annual ROTH Conference

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology firm, announced that CEO Gail McIntyre will participate in the 34th Annual ROTH Conference on March 14, 2022, at 8:30 am PT. The event will take place at The Ritz Carlton, Dana Point, California. McIntyre and CFO Vinay Shah will also hold one-on-one meetings on the same day. Aravive is advancing treatments targeting metastatic disease, with its lead candidate, batiraxcept, showing promise in clinical trials for ovarian cancer and other cancers. A live webcast of the presentation will be accessible on their website.

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, will participate in an in-person fireside chat at the 34^th Annual ROTH Conference on Monday, March 14, 2022, at 8:30 am PT in HEALTHCARE VFC – Suite 2022 at The Ritz Carlton, Dana Point, California. Dr. McIntyre and Vinay Shah, Chief Financial Officer of Aravive, will be available for one-on-one meetings on Monday, March 14^th.

A live webcast and a replay of the presentation will be available on Events & Presentations page of www.aravive.com.

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). Additional information at www.aravive.com.

Contact:
Marek Ciszewski, J.D.
Vice President, Investor Relations
Marek@Aravive.com
(562) 373-5787

 

FAQ

What event will Aravive participate in on March 14, 2022?

Aravive will participate in the 34th Annual ROTH Conference on March 14, 2022.

Who is speaking at the ROTH Conference for Aravive?

CEO Gail McIntyre and CFO Vinay Shah will represent Aravive at the conference.

What time is Aravive's presentation at the ROTH Conference?

Aravive's presentation is scheduled for 8:30 am PT on March 14, 2022.

Where is the ROTH Conference taking place?

The conference will take place at The Ritz Carlton in Dana Point, California.

Is there a way to watch Aravive's presentation online?

Yes, a live webcast and replay of Aravive's presentation will be available on their Events & Presentations page.

What is batiraxcept and its significance for Aravive?

Batiraxcept is Aravive's lead therapeutic candidate targeting metastatic disease, currently in various clinical trials.